Exciting Progress in ALS Research: Introducing the HEALEY ALS MyMatch Early Phase Trial

We are proud to share an important research update from the Sean M. Healey & AMG Center for ALS at Mass General Hospital—a key partner in the fight against ALS and the recipient of funding from the Richard J. Wolnik Foundation.

The newly launched HEALEY ALS MyMatch: Early Phase Trial represents a groundbreaking approach to tackling the complexity of ALS. By using advanced AI tools and biomarker-driven methods, this initiative aims to match specific subgroups of people living with ALS to experimental therapies based on their disease mechanisms. This innovative research is helping accelerate the path toward more personalized treatments—and ultimately, a cure.

We’re proud to support the Healey & AMG Center and remain dedicated to raising funds that drive research forward and offer hope to those affected by ALS.

You can read the full update from the Healey Center below:

📄 Download the Full Overview – HEALEY ALS MyMatch Early Phase Trial (PDF)